Lung cancer survival rates are up thanks to immunotherapy, other ... - NPR
WEBApr 12, 2024 · Lung cancer remains the most lethal form of the disease, killing about 135,000 Americans a year – more than breast, prostate and colon cancer combined – which is why many people still think of...
Osimertinib Improves Survival in Lung Cancer - NCI
WEBJul 5, 2023 · Improved overall survival with osimertinib. The initial results from ADAURA, published in October 2020, offered signs of possible survival improvements with adjuvant osimertinib. This treatment, they showed, dramatically improved how long people lived without any evidence of their cancer returning.
Lung cancer treatment produces progression-free survival results …
WEBJun 5, 2024 · The positive results from the LAURA Phase III trial underscore the importance of early testing and diagnosis in lung cancer, which remains the leading cause of cancer death worldwide,...
Adjuvant durvalumab extends survival in small cell lung cancer
WEB2 days ago · For patients with limited-stage small cell lung cancer, adjuvant therapy with durvalumab leads to significantly longer overall and progression-free survival, according to a study published online ...
US lung cancer survival rates rise, but it’s still the leading ... - CNN
WEBNov 14, 2023 · CNN — Over the past five years, the five-year survival rate for lung cancer in the US has increased a significant 22%, according to a new report from the American Lung Association. But the...
Targeted Drug Stops Lung Cancer Growth for Five Years in Over …
WEBJun 13, 2024 · A study shows that a targeted therapy drug stops the spread of lung cancer for 5 years or more. The drug, lorlatinib (Lobrena), also stops new cancer growth in the brain. These benefits were seen in 3 out of every 5 people with advanced non-small cell lung cancer (NSCLC) with an ALK gene mutation.
Sotorasib is First KRAS Inhibitor Approved by FDA - NCI
WEBJun 25, 2021 · The CodeBreaK 100 trial, funded by Amgen and NCI, is testing sotorasib (previously called AMG510) as a treatment for people with solid tumors that have KRAS G12C. The mutation, a hallmark of damage from cigarette smoke, is …
Repotrectinib Shrinks ROS1-Positive NSCLC Tumors - NCI
WEBFeb 16, 2024 · Treatment with repotrectinib can shrink tumors in people with advanced lung cancer whose tumors have ROS1 fusions. FDA approved the drug in 2023 as an initial or second-line treatment for ROS1-positive NSCLC.
Pfizer’s Lorbrena extends life for patients with rare lung cancer
WEBMay 31, 2024 · Pfizer’s lung cancer drug Lorbrena can extend life for patients with a rare form of the disease for years longer than other drugs, according to new research published Friday. The drug treats a...
New lung cancer drug an ‘impressive one-two punch’
WEBIn cancer, especially lung cancer, extending survival is really the name of the game. Osimertinib already has an average progression-free survival of 16.6 months, but for the Rybrevant-Lazcluze therapy to extend that to nearly two full years, 23.7 months, is significant for patients.